Skip to main content
. 2020 Jan 14;14(3):645–656. doi: 10.1002/1878-0261.12627

Figure 6.

Figure 6

In vivo efficacy of SG: (A) antitumor activity and (B) overall survival of SG were compared to controls including control ADC, unconjugated mAb (hRS7 IgG), and saline, in EC xenograft models (i.e., END(K)265, 3+ Trop‐2‐positive). (C) Mice weight change during treatment. Mice were treated intravenously with twice‐weekly doses for 3 weeks as described in Methods. (A) A significant difference in tumor growth inhibition was detected beginning on day 4 (P < 0.05) in the SG‐treated group when compared to the other control groups. (B) Median survival for the SG group was 40 days, compared to 15 days for control ADC and 11 days for hRS7 and saline. Error bars indicate standard deviation (SD) in both (A) and (C).